Work

122P Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist

Year: 2024

Type: article

Abstract: Conclusions: In this study population, the addition of antieIL-8 to NIVO + IPI was well tolerated, but no statistically significant difference for the primary endpoint of ORR or the secondary endpoint of PFS was observed in patients with advanced melanoma who had progressed on/after anti-PD-(L)1 therapy.Clinical trial identification: NCT03400332.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2024.100751

Authors: E. Houthuys, T. Sanders, C. Nabel, M. Brouwer, A. Hermant, L. Chaible, J-P. Deglasse, A. Pabois, W. Cathou, A. Smets, M. Deligny, J. Marchante, Q. Dubray, M-C. Letellier, C. Martinoli, R. Marillier, O. De Henau, Y. McGrath, M. Vander Heiden

Institutions: Koch Institute for Integrative Cancer Research At MIT, Massachusetts Institute of Technology

Language: English

Topic: Adenosine and Purinergic Signaling

Subfield: Physiology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,170

Funders: AstraZeneca, PharmaMar, CRIS Cancer Foundation

OpenAlex ID: W4405374745

FWCI:

Cites:

Cited by:

Related to: 10